Foreword  by Klugman, Keith & Poole, Michael D.
RESPIRATORY MEDICINE (2001) 95 BJPPLEMENT A), Sl 
doi:10.1053/rmed.2001.1085, available online at http://www.idealibrary.com on lOE)$ 
Foreword 
Bacterial respiratory infections: 
closing in on antibiotic effectiveness 
. . . and ineffectiveness 
The global dissemination of highly antibiotic-resistant 
respiratory pathogens presents a challenge to clinicians 
caring for individual patients as well as a challenge to the 
community of researchers in microbiology and respiratory 
medicine to provide rational approaches to the control of 
this problem. The individual reviews in this supplement 
represent a sample of our current understanding about 
issues surrounding antimicrobial efficacy and resistance in 
respiratory infections. The last decade has seen a conver- 
gence of data sets that is consistent and clear. 
As a leader in the field of antimicrobial pharmacokinetic/ 
pharmacodynamic (PK/PD) issues relative to respiratory 
infections, Dr William Craig’s animal models have defined 
those parameters associated with treatment success, and 
given us a basis for predicting treatment failures. Those 
predictions are consistent with results in the ‘double-tap’ 
studies in otitis media and sinusitis, conducted by Dr Ron 
Dagan and others. The Nordic countries have taken the 
lead in community-based programs to control antimicro- 
bial resistance. Dr Otto Cars from Sweden has reviewed the 
drivers of resistance in the community and summarized the 
attempts made so far to limit unnecessary antibiotic use. An 
understanding of the clinical relevance of resistance is 
essential to the design of appropriate therapeutic strategies. 
Dr Javier Garau from Spain has summarized this field and 
provides new data on the clinical relevance of macrolide 
resistance in the pneumococcus. 
Because of the generally favorable natural history of 
most bacterial respiratory infections, and to a degree 
because of clinicians’ limitations in their ability to 
distinguish viral from bacterial infections, the actual 
antimicrobial efficacy of any given agent can be hard to 
discern. Hundreds of millions of dollars are currently spent 
on oral antimicrobials that are bacteriologically ineffective 
against the antibiotic-resistant pathogens for which they are 
prescribed. How do we deal with those relatively inactive 
agents? What is the magnitude of the costs and morbidities 
associated with these less optimal choices? How can we 
interpret clinical trials that are not designed or powered to 
reveal differences between effective and ineffective agents? 
The authors here lay the scientific groundwork for tackling 
difficult tasks: changing behavior that may adversely affect 
our patients. Recent national guidelines are helpful. In 
short, the data are compelling: We need to move on to the 
next step-the implementation of antimicrobial therapy 
based on sound pharmacodynamic principles. 
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